erlotinib hydrochloride has been researched along with Chordoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Asquith, CRM; Bieberich, AA; Crona, DJ; Fatig, RO; Laitinen, T; Maffuid, K; Morris, DC; Torrice, CD | 1 |
| Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Bonneville-Levard, A; Chauffert, B; Chevreau, C; Cupissol, D; Duffaud, F; Fabbro, M; Feuvret, L; Le Cesne, A; Lebellec, L; Mir, O; Noel, G; Penel, N; Saada-Bouzid, E; Vauleon, E; Vinceneux, A | 1 |
| Bettegowda, C; Burger, PC; Connis, N; Gallia, GL; Hann, CL; Jiao, Y; Ruzevick, J; Siu, IM; Xia, X; Zhao, Q | 1 |
| Asklund, T; Henriksson, R; Riklund, K; Sandström, M; Shahidi, S | 1 |
| Amary, F; Barnard, M; Brüderlein, S; Cottone, L; Drewry, DH; Flanagan, AM; Guppy, N; Jorgensen, M; Leite, AP; Leithner, A; Möller, P; Pillay, N; Scheipl, S; Smith, JA; Strauss, SJ; Tirabosco, R; Turlais, F; Ye, H; Zuercher, WJ | 1 |
| Kotasek, D; Parnis, FX; Singhal, N | 1 |
| Bertucci, F; Chetaille, B; Guiramand, J; Launay, SG; Medina, F; Moureau-Zabotto, L; Nazarian, S; Perrot, D | 1 |
1 review(s) available for erlotinib hydrochloride and Chordoma
| Article | Year |
|---|---|
Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chordoma; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Male; Molecular Targeted Therapy; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Treatment Outcome | 2011 |
6 other study(ies) available for erlotinib hydrochloride and Chordoma
| Article | Year |
|---|---|
Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform.
Topics: Aniline Compounds; Chordoma; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chordoma; Erlotinib Hydrochloride; Female; France; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Skull Base Neoplasms; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Erlotinib inhibits growth of a patient-derived chordoma xenograft.
Topics: Animals; Cell Line, Transformed; Cell Proliferation; Chordoma; ErbB Receptors; Erlotinib Hydrochloride; Genome-Wide Association Study; Heterografts; Humans; Mice; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Durable stabilization of three chordoma cases by bevacizumab and erlotinib.
Topics: Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Bone Neoplasms; Chordoma; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Quinazolines; Sacrum; Skull Neoplasms; Treatment Outcome | 2014 |
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chordoma; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mice; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Response to erlotinib in a patient with treatment refractory chordoma.
Topics: Antineoplastic Agents; Chordoma; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sacrococcygeal Region | 2009 |